Biomarker ID | 604 |
PMID | 21367627 |
Year | 2011 |
Biomarker | Stromal cell-derived factor-1 (SDF-1) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Patients with low levels survived longer than those with high levels |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 5.164 (95% CI: 2.645–10.083); Multivariate: HR: 2.840 (95% CI: 1.203–6.708) |
Effect on Pathways | Pathways Include:- Binding of chemokines to chemokine receptors, Nuclear signaling by ErbB4,Intestinal immune network for IgA production,HIF-1 transcriptional activity in hypoxia,Interleukin-7 interactions in immune response |
Experiment | Prostate Cancer Specific Survival VS No Survival |
Type of Biomarker | Prognostic |
Cohort | 148 CaP patients who underwent radical prostatectomy for clinically localized disease and 10 samples of benign prostatic hyperplasia (BPH) were chosen for the study. Lymph Node Metastatis Posititve(n=10) and Lymph Node Metastatis Negative (n=138) |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | Univariate: p<0.001; Multivariate: p=0.017 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | CXCL12 |